MX2022013002A - Vacunas de coronavirus con reacción amplia genéticamente modificadas y diseños y usos relacionados. - Google Patents

Vacunas de coronavirus con reacción amplia genéticamente modificadas y diseños y usos relacionados.

Info

Publication number
MX2022013002A
MX2022013002A MX2022013002A MX2022013002A MX2022013002A MX 2022013002 A MX2022013002 A MX 2022013002A MX 2022013002 A MX2022013002 A MX 2022013002A MX 2022013002 A MX2022013002 A MX 2022013002A MX 2022013002 A MX2022013002 A MX 2022013002A
Authority
MX
Mexico
Prior art keywords
cov
group
sequence
homology
viral vector
Prior art date
Application number
MX2022013002A
Other languages
English (en)
Inventor
Uwe D Staerz
Daniel F Preston
Original Assignee
Greffex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greffex Inc filed Critical Greffex Inc
Publication of MX2022013002A publication Critical patent/MX2022013002A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una vacuna para prevenir la infección ß-CoV incluye por lo menos un vector viral que contiene una secuencia de ADN de ß-CoV que codifica la proteína S para el ß-CoV. La secuencia de ARN de ß-CoV puede ser una secuencia de ADN de SARS-2 ß-CoV. La vacuna además incluye un plásmido de empaquetamiento en base a un adenovirus. El vector viral y el plásmido de empaquetamiento pueden ser contenidos en una célula de empaquetamiento y encapsidados en una cápside. Un método para vacunar a un sujeto mamífero contra la infección de por lo menos un grupo de ß-CoV incluye separar un grupo amplio de ß-CoV en grupos de homología en base a similitudes en las secuencias de ARN de ß-CoV que codifican para sus proteínas S, identificar por lo menos una secuencia de consenso para cada grupo de homología que tiene una identidad de secuencia de mayor que 60% a todos los otros miembros del grupo de homología, y preparar un vector viral que incluye por lo menos una porción de la secuencia de consenso de por lo menos un grupo de homología.
MX2022013002A 2020-04-20 2021-04-20 Vacunas de coronavirus con reacción amplia genéticamente modificadas y diseños y usos relacionados. MX2022013002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063012360P 2020-04-20 2020-04-20
PCT/US2021/028187 WO2021216569A1 (en) 2020-04-20 2021-04-20 Engineering broadly reactive coronavirus vaccines and related designs and uses

Publications (1)

Publication Number Publication Date
MX2022013002A true MX2022013002A (es) 2023-03-10

Family

ID=78270059

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013002A MX2022013002A (es) 2020-04-20 2021-04-20 Vacunas de coronavirus con reacción amplia genéticamente modificadas y diseños y usos relacionados.

Country Status (7)

Country Link
US (1) US20230210979A1 (es)
EP (1) EP4138902A4 (es)
JP (1) JP2023522108A (es)
CN (1) CN116096410A (es)
CA (1) CA3175650A1 (es)
MX (1) MX2022013002A (es)
WO (1) WO2021216569A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE2250542A1 (en) * 2022-05-03 2023-11-04 Andrell Juni Ancestral protein sequences and production thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117961A1 (fr) * 2004-06-04 2005-12-15 Cancer Center Sun Yat-Sen University Vaccin contre le virus du sras a vecteur d'adenovirus et procede d'elaboration, et utilisation de gene s du virus du sras pour l'elaboration de ce vaccin
US20070190065A1 (en) * 2005-06-03 2007-08-16 Ralf Altmeyer Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
CN110951756B (zh) * 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
CN110974950B (zh) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗

Also Published As

Publication number Publication date
CN116096410A (zh) 2023-05-09
WO2021216569A1 (en) 2021-10-28
CA3175650A1 (en) 2021-10-28
EP4138902A1 (en) 2023-03-01
US20230210979A1 (en) 2023-07-06
EP4138902A4 (en) 2024-06-12
JP2023522108A (ja) 2023-05-26

Similar Documents

Publication Publication Date Title
Hosamani et al. Differentiation of sheep pox and goat poxviruses by sequence analysis and PCR-RFLP of P32 gene
Sangula et al. Low diversity of foot-and-mouth disease serotype C virus in Kenya: evidence for probable vaccine strain re-introductions in the field
US7722878B2 (en) PRRSV subunit vaccines
Toro et al. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector
Publicover et al. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector
Li et al. Isolation, identification, and whole genome sequencing of reticuloendotheliosis virus from a vaccine against Marek's disease
Vignuzzi et al. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein
Staib et al. Improved host range selection for recombinant modified vaccinia virus Ankara
CN100425291C (zh) O型口蹄疫病毒多基因复制缺陷型腺病毒活载体疫苗及制备方法
CN101775399B (zh) 牛口蹄疫病毒Asial型多表位重组疫苗及制备方法
MX2022013002A (es) Vacunas de coronavirus con reacción amplia genéticamente modificadas y diseños y usos relacionados.
Holman et al. A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity
CA3080427A1 (en) Feline leukemia virus vaccine
CN105797152A (zh) 一种疫苗组合物及其制备方法和应用
CN105617373A (zh) 一种疫苗组合物及其制备方法和应用
RU2013102929A (ru) Пан-лиссавирусные вакцины против бешенства
López et al. Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs
US20220023413A1 (en) Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
Jang et al. Genetic and pathologic characterization of a novel recombinant TC07-2-type avian infectious bronchitis virus
CN102274523A (zh) 一种猪圆环病毒ⅱ型核酸疫苗及其制备方法
Moon et al. Genomic characteristics of natural recombinant infectious bronchitis viruses isolated in Korea
AP2000001892A0 (en) Self-replicating vector for DNA immunization against HIV.
WO2022031683A1 (en) Synthetic defective interfering coronaviruses
Lu et al. An African swine fever virus gene with a similarity to eukaryotic RNA polymerase subunit 6.
CN108384763A (zh) 一种传染性脾肾坏死病毒orf074基因缺失株及其制备方法和应用